About
About Nichi-Iko Pharmaceutical Co., Ltd
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, and distributes various pharmaceutical products. It operates through two segments, Nichi-Iko Group and Sagent Group. The company primarily focuses on the production of generic drugs. It offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin " antagonist, angiotensin " antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products, as well as chemotherapeutic agents. The company also provides treatments for circulatory, digestive, respiratory, nervous system, allergies, and others. It supplies its products to medical institutions, including hospitals, clinics, dispensing pharmacies, etc. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was incorporated in 1947 and is headquartered in Toyama, Japan.
Visit company website
5 years, 6 months ago
Nichi-Iko Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 14.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.3.
Nichi-Iko Pharmaceutical Co., Ltd's total revenue sank by 2.8% to $49B since the same quarter in the previous year.
Its net income has dropped by 114.4% to $-362M since the same quarter in the previous year.
Finally, its free cash flow grew by 640.1% to $1B since the same quarter in the previous year.
Based on the above factors, Nichi-Iko Pharmaceutical Co., Ltd gets an overall score of 2/5.